Press Releases

Date Title  
Toggle Summary Audentes Therapeutics Announces Pricing of Public Offering of Common Stock
SAN FRANCISCO , Oct. 10, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the pricing of its
Toggle Summary Audentes Therapeutics Announces Proposed Public Offering of Common Stock
SAN FRANCISCO , Oct. 9, 2018 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, announced today that it intends to offer
Toggle Summary Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society
SAN FRANCISCO , Oct. 5, 2018 /PRNewswire/ -- Conference call and webcast Friday, October 5, 2018 at 8:30 am ET Webcast may be accessed via the Investor and Media page of the Audentes website Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference
Toggle Summary Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society
- Significant continued improvements in neuromuscular and respiratory function observed in all treated patients, with follow-up assessments ranging from 4 to 48 weeks - Three patients have achieved complete ventilator independence - Encouraging initial safety and efficacy results observed in Cohort
Toggle Summary Audentes Therapeutics Announces Co-Founder and Chief Executive Officer Matthew R. Patterson Appointed Chairman of the Alliance for Regenerative Medicine
SAN FRANCISCO , Oct. 3, 2018 /PRNewswire/ --  Audentes Therapeutics, Inc.  (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Co-Founder and Chief
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Sept. 26, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate
Toggle Summary Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society
- Oral presentation to include new data from ASPIRO out to 48-weeks of follow-up in the earliest treated patients in dose Cohort 1, and preliminary safety and efficacy data from the sentinel patient in dose Cohort 2 - Oral presentation to be held during a session on new therapeutic modalities
Toggle Summary Audentes Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO , Aug. 29, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that it will participate in
Toggle Summary Audentes Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by the FDA to AT132 for the Treatment of X-Linked Myotubular Myopathy
- Designation granted based on positive interim data from ASPIRO clinical trial - RMAT designation enables closer and more frequent multidisciplinary interaction with FDA and includes all of the benefits of breakthrough therapy designation - Plan to meet with FDA to gain alignment on AT132
Toggle Summary Audentes Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference
SAN FRANCISCO , Aug. 9, 2018 /PRNewswire/ -- Audentes Therapeutics , Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing innovative gene therapy products for patients living with serious, life-threatening rare diseases, today announced that Natalie Holles ,